No Data
No Data
Express News | Dianthus Therapeutics Files for Resale of up to 23.7 Mln Shares of Common Stock by Selling Stockholders - SEC Filing
H.C. Wainwright Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $40
Promising Outlook for Dianthus Therapeutics' DNTH103 as a Best-in-Class C1s Inhibitor
Hesperos Provides Support for an Investigational Product for a Phase II Clinical Trial With Its Human-on-a-Chip
Dianthus Therapeutics to Participate in Three Healthcare Investor Conferences in September
Ulta Beauty Reports Downbeat Results, Joins Elastic And Other Big Stocks Moving Lower In Friday's Pre-Market Session